Novel Targets in the Ovarian Cancer Treatment Paradigm | Supplements And Featured Publications

The Novel Targets in the Ovarian Cancer Treatment Paradigm publication covers some of the latest practice-changing advances as it relates to novel targets in the treatment for patients with advanced ovarian cancer.


Upifitamab Rilsodotin Under Investigation in Several Trials to Bridge Unmet Need in Recurrent Ovarian Cancer

February 04, 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.